D-Index & Metrics Best Publications
Michael Pfreundschuh

Michael Pfreundschuh

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 95 Citations 37,517 504 World Ranking 4708 National Ranking 213

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

His primary scientific interests are in Internal medicine, Surgery, Lymphoma, Immunology and Oncology. His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology. Michael Pfreundschuh combines subjects such as Hematology and BCL6 with his study of Lymphoma.

He usually deals with Immunology and limits it to topics linked to Stem cell and DNA damage, Adult stem cell and Stem cell theory of aging. His Oncology research is multidisciplinary, incorporating perspectives in Survival rate, Mantle cell lymphoma, Radiation therapy and Standard treatment. His study in Antigen is interdisciplinary in nature, drawing from both Cancer, Cancer research, Melanoma, Immune system and Antibody.

His most cited work include:

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group (1582 citations)
  • A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening (1112 citations)
  • Human neoplasms elicit multiple specific immune responses in the autologous host. (1013 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Immunology, Oncology, Surgery and Lymphoma are his primary areas of study. His research combines Gastroenterology and Internal medicine. The Oncology study combines topics in areas such as Imatinib, Myeloid leukemia, Radiation therapy and Mantle cell lymphoma.

His research integrates issues of Hematology, Cancer research and B cell in his study of Lymphoma. His work in CHOP addresses subjects such as Vincristine, which are connected to disciplines such as Prednisone. His biological study spans a wide range of topics, including Molecular biology, Cytotoxic T cell and Antibody, Serology.

He most often published in these fields:

  • Internal medicine (50.85%)
  • Immunology (29.35%)
  • Oncology (25.43%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (50.85%)
  • Oncology (25.43%)
  • Lymphoma (22.18%)

In recent papers he was focusing on the following fields of study:

Michael Pfreundschuh spends much of his time researching Internal medicine, Oncology, Lymphoma, Diffuse large B-cell lymphoma and Rituximab. His Internal medicine research includes themes of Gastroenterology and Surgery. His Oncology study which covers Multiple myeloma that intersects with Dexamethasone.

His research investigates the link between Lymphoma and topics such as Cancer research that cross with problems in Antigen, B-cell receptor and Cell culture. His Diffuse large B-cell lymphoma study also includes fields such as

  • Progression-free survival which is related to area like Clinical trial and Aggressive lymphoma,
  • Family medicine which connect with MEDLINE. As part of one scientific family, Michael Pfreundschuh deals mainly with the area of Rituximab, narrowing it down to issues related to the Vincristine, and often Prednisone.

Between 2015 and 2021, his most popular works were:

  • Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes (447 citations)
  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
  • Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. (162 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His scientific interests lie mostly in Internal medicine, Lymphoma, Surgery, Rituximab and Oncology. His Internal medicine study frequently draws parallels with other fields, such as Gastroenterology. His Lymphoma study is related to the wider topic of Pathology.

His study explores the link between Surgery and topics such as Hazard ratio that cross with problems in Pharmacokinetics. His studies in Rituximab integrate themes in fields like Vincristine, B-cell lymphoma, Chemotherapy and Prednisone. His work deals with themes such as Cytarabine, Malignancy, Retrospective cohort study and Chemoimmunotherapy, which intersect with Oncology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell.
Lancet Oncology (2006)

2620 Citations

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Yao-Tseng Chen;Matthew J. Scanlan;Ugur Sahin;Özlem Türeci.
Proceedings of the National Academy of Sciences of the United States of America (1997)

1499 Citations

Human neoplasms elicit multiple specific immune responses in the autologous host.

Ugur Sahin;Ozlem Tureci;Holger Schmitt;Bjorn Cochlovius.
Proceedings of the National Academy of Sciences of the United States of America (1995)

1443 Citations

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh;Joerg Schubert;Marita Ziepert;Rudolf Schmits.
Lancet Oncology (2008)

1092 Citations

Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

Volker Diehl;Jeremy Franklin;Michael Pfreundschuh;Bernd Lathan.
The New England Journal of Medicine (2003)

1044 Citations

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari.
Journal of Clinical Oncology (2012)

923 Citations

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht.
Blood (2006)

879 Citations

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg.
Lancet Oncology (2011)

680 Citations

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Andreas Engert;Heinz Haverkamp;Carsten Kobe;Jana Markova.
The Lancet (2012)

607 Citations

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era

Marita Ziepert;Dirk Hasenclever;Evelyn Kuhnt;Bertram Glass.
Journal of Clinical Oncology (2010)

577 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Michael Pfreundschuh

Lloyd J. Old

Lloyd J. Old

Ludwig Cancer Research

Publications: 193

Andreas Engert

Andreas Engert

University of Cologne

Publications: 174

Volker Diehl

Volker Diehl

University of Cologne

Publications: 133

Martin Dreyling

Martin Dreyling

Ludwig-Maximilians-Universität München

Publications: 132

Yao-Tseng Chen

Yao-Tseng Chen

Cornell University

Publications: 121

Gilles Salles

Gilles Salles

Memorial Sloan Kettering Cancer Center

Publications: 111

Randy D. Gascoyne

Randy D. Gascoyne

BC Cancer Agency

Publications: 108

Wolfram Klapper

Wolfram Klapper

Kiel University

Publications: 97

Jonathan W. Friedberg

Jonathan W. Friedberg

University of Rochester

Publications: 87

John F. Seymour

John F. Seymour

Peter MacCallum Cancer Centre

Publications: 84

Andreas Rosenwald

Andreas Rosenwald

University of Würzburg

Publications: 80

Hervé Tilly

Hervé Tilly

Inserm : Institut national de la santé et de la recherche médicale

Publications: 79

L. Jeffrey Medeiros

L. Jeffrey Medeiros

The University of Texas MD Anderson Cancer Center

Publications: 79

Alexander Knuth

Alexander Knuth

University of Zurich

Publications: 79

Joseph M. Connors

Joseph M. Connors

University of British Columbia

Publications: 77

Umberto Vitolo

Umberto Vitolo

University of Turin

Publications: 76

Something went wrong. Please try again later.